Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01225393 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis

A Phase 2 study, sponsored by Genentech.

Completed
Registry status
Phase 2
Development phase
211
Enrollment target

NCT01225393: Completed Phase 2 study, sponsored by Genentech.

NCT01225393 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 211 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01225393, a Phase 2 study, has completed, sponsored by Genentech.

COMPLETED
Registry status
Phase 2
Development phase
211 participants
Enrollment target

Study Summary

This is a Phase II, randomized, double-blind, placebo-controlled, parallel-group, multicenter study enrolling patients with active rheumatoid arthritis (RA).

Interventions

  • DRUG placebo
  • DRUG methotrexate
  • DRUG adalimumab
  • DRUG leflunomide
  • DRUG MLTA3698A

Trial Details

FieldValue
Enrollment Target 211 participants
Start Date 2010-11
Phase Phase 2
Genentech

332 total trials

What the finished NCT01225393 record still lists

NCT01225393 is an interventional study that assigns participants to a tested intervention. The registered 211 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% higher).

The record links to 0 conditions, and to 5 interventions - of which placebo is the first listed.

NCT01225393 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01225393 about?

NCT01225393 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis". This is a Phase II, randomized, double-blind, placebo-controlled, parallel-group, multicenter study enrolling patients with active rheumatoid arthritis (RA).

What is the current status of trial NCT01225393?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 211 participants. The study started on 2010-11.

What interventions are being tested in trial NCT01225393?

The interventions under investigation include: placebo (DRUG), methotrexate (DRUG), adalimumab (DRUG), leflunomide (DRUG), MLTA3698A (DRUG).

Who is sponsoring clinical trial NCT01225393?

This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01225393's enrollment target sits among peer trials

211 290th of 2000 higher than 1,711 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06698796 · 211 participants · Phase 3

    A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies

  • NCT04228978 · 212 participants · NA

    Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss

  • NCT04725721 · 212 participants · NA

    Testing FIRST in Youth Outpatient Psychotherapy

  • NCT06257576 · 212 participants · Phase 3

    Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01225393, the US trial registry maintained by the National Library of Medicine. NCT01225393 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.